The Impact of Governmental Policy on R&D Projects in the Pharmaceutical Industry
Keywords:
government policy, pharmaceutical pricing, R&D projects, pharmaceutical industryAbstract
Most of the countries worldwide have strong regulations on drug markets, in order to cope with the rising costs of health care. On the other hand, the regulations violate the incentives for investment in pharmaceutical R&D projects. Thus, in order to stimulate R&D activity, and at the same time to regulate pharmaceutical market, every government is obligated to create balanced reforms for pharmaceutical market. This paper presents the policies for fostering innovations and regulations in the pharmaceutical market in R. Bulgaria and R. Macedonia. The comparison with the regulations and stimulations for pharmaceutical market in USA and other EU countries will help in creating the most corresponding programme, both for the customers and pharmaceutical companies.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
Civan, A., Maloney M.T. (2009), „The effect of price on pharmaceutical R&D“, The B.E. Journal of Economic Analysis Policy, Vol. 9 No. 1, pp. 18-25.
Danzon, P. M., Chao, L. W. (2000), „Cross-national price differences for pharmaceuticals: how large, and why?“JHealthEcon, Vol. 19 No. 2, pp. 159–195.
Eger, S., Mahlich, J. C. (2014), „Pharmaceutical regulation in Europe and its impact on corporate R&D“, Health Economics Review, Vol. 4 No. 23, pp. 1–9.
Giaccotto, C. et al. (2003), „Drug Prices and R&D Investment Behaviour in the Pharmaceutical Industry“, USA, University of Connecticut.
Glans, M. (2014), „Research & Commentary: “Right to Try” Experimental Drug Laws“, available at: https://www.heartland.org/policy-documents/research-commentary-right-try-experimental-drug-laws (accessed April 15th 2015)
Grabowsky, H., Vernon, J. (2000), „The Determinants of Pharmaceutical Research and Development Expenditures“, Journal of Evolutionary Economics, Vol. 10 No.1-2, pp. 201- 215.
Koenig, P., McGarvie, M. (2011), „Regulatory policy and the location of bio-pharmaceutical foreign direct investment in Europe“, Journal of Health Economics, Vol. 30 No. 5, pp. 950–965.
Kremer, M., (2002), „Pharmaceuticals and the Developing World“, The Journal of Economic Perspectives, Vol. 16 No. 4, pp. 67-90.
Kyle, M., (2007), „Pharmaceutical Price Controls and Entry Strategies“, The Review of Economics and Statistics, Vol. 89 No.1, pp. 88–99.
Light, D.W., Lexchin, J.R. (2012), „Research and development: what do we get for all that money?“, BMJ, pp. 345-348.
Lichtenberg, F.R. (2005), „Pharmaceutical Knowledge-Capital Accumulation and Longevity“, Measuring Capital in the New Economy, Chicago: University of Chicago Press, available at: http://www.nber.org/chapters/c10623 (accessed February 23rd 2015).
Lokshin, B., Mohnen P. (2009), „What Does it Take For an R&D Tax Incentive Policy to be Effective?“, Working Paper IEB 2009/9, Institut d’Economia de Barcelona.
Love, J., Hubbard, T. (2007), „The Big Idea: Prizes to Stimulate R&D for New Medicines“, Chicago – Kent Law Review, Vol. 82 No.3, pp. 1519 – 1554.
Mohnen, P. et al. (2008), „Financial Constraints and Other Obstacles: Are they a Threat to Innovation Activity?“, Working Paper Series [#2008-006], United Nations University, The Netherlands.
Porter, M.E., van der Linde, C. (1995), „Toward a New Conception of the Environment Competitiveness Relationship“, The Journal of Economic Perspectives, Vol.9 No.4, pp. 97–118.
Rudholm N. (2002), „Economic implications of antibiotic resistance in a global economy“, Journal of Health Economics, Vol.21 No.6, pp. 1071-83.
Sood, N. et al. (2009),„The effect of regulation on pharmaceutical revenues: experience in nineteen countries“, Health Affairs, Vol. 28 No. 1, pp. 125–137.
Vernon, A. J. (2004), „New Evidence on Drug Price Control“, Cato Institute, USA.
